Corcept Therapeutics

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

As of late, it has definitely been a great time to be an investor Corcept Therapeutics.

Can The Uptrend Continue for Corcept Therapeutics?

Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Corcept (CORT) Stock

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2019 Results - Earnings Call Transcript

Corcept (CORT) rides high on both earnings and revenue beat in the third quarter.

Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales

Corcept (CORT) delivered earnings and revenue surprises of 15.79% and 5.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Surpasses Q3 Earnings and Revenue Estimates

Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Corcept (CORT) is Poised to Beat Earnings Estimates Again

MENLO PARK, Calif., Sept.  18, 2019  (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Kimberly Park has joined the company’s Board of Directors.

Corcept Therapeutics Appoints Kimberly Park to Board of Directors

Atrion

Merit Medical Systems

National Research Corp

Supernus Pharmaceuticals

According to the GuruFocus All-In-One Screener as of Friday, the following health care stocks are popular among gurus.

5 Health Care Stocks - Gurus Are Buying

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Corcept (CORT) Up 15.1% Since Last Earnings Report: Can It Continue?

MENLO PARK, Calif., Aug.  28, 2019  (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the administration of Korlym® with food.  The patent will expire in November 2032.

Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome

Liver Therapy Forum weekly digest provides an overview of what’s happening in therapeutics for endocrine disease in 2019. This week’s focus is Corcept Therapeutics.

Corcept Therapeutics And Relacorilant In Cushing's Syndrome

Corcept (CORT) misses earnings and revenue estimates in the second quarter of 2019.

Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2

Corcept Therapeutics Inc. (CORT) CEO Joseph Belanoff on Q2 2019 Results - Earnings Call Transcript

Corcept (CORT) delivered earnings and revenue surprises of 38.89% and -0.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Q2 Earnings Beat Estimates

Corcept (CORT) Down 11.3% Since Last Earnings Report: Can It Rebound?

Corcept Therapeutics Inc. (CORT) CEO Joseph Belanoff on Q1 2019 Results - Earnings Call Transcript

Corcept (CORT) delivered earnings and revenue surprises of 11.11% and -3.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Q1 Earnings Top Estimates

Corcept's Cushing's syndrome drug Korlym shows a steady progress. The company's efforts to expand the drug's label also hold promise and bode well for long-term growth.

Corcept Rides High on Cushing's Syndrome Drug Korlym

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept (CORT) Down 6.1% Since Last Earnings Report: Can It Rebound?

The stock ricocheted around, but ultimately posted a monthly gain.

News for Corcept Therapeutics Stock (CORT)